[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:ros1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","ROS1 Gene",9,[8,16,23,29,35,41,47,53,59],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05118789","A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:08.402952Z","2026-05-05T02:43:29.649189Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06716138","A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors",[20],"Phase 1","2026-08-26T02:15:56.561131Z","2026-05-05T02:43:29.330388Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04693468","Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial",[20],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:28.961863Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06307795","A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors",[20],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:28.368425Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT04094610","A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations",[12],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:27.807992Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05004116","A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer",[12],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.261412Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[20],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT03093116","A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",[12],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:27.489051Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[12],"2026-08-26T02:19:10.436356Z","2026-04-29T02:57:57.121665Z"]